Clearside Biomedical (CLSD): Notes From Expert Call - Wedbush
- Wall Street again marks new highs in post-election run
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- After-Hours Stock Movers 12/08: (FNSR) (AVGO) (GLPG) Higher; (XTLY) (RH) (DLTH) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Clearside Biomedical (NASDAQ: CLSD) after hosting an expert call with Dr. Seenu Hariprasad from the University of Chicago who has direct experience with SCS delivery and Clearside’s clinical product candidates.
Ms Moussatos noted "Dr. Hariprasad focused on drug candidates which reduce treatment burden and improve safety while maintaining or improving efficacy. In Phase 2, Clearside’s Zuprata has already demonstrated reduced treatment burden with 60% fewer injections of Eylea in combination with Zuprata for macular edema associated with retinal vein occlusion (ME-RVO). In addition, Zuprata improved safety (no drug-related elevation in IOP or cataracts in either Phase 2 trial) with equal to or better efficacy in terms of reducing retinal thickness and rapidly and durably improving visual acuity in both Phase 2 trials for macular edema associated with non-infectious uveitis (ME-NIU) and for ME-RVO."
The analyst further stated "He sees the potential for Clearside’s proprietary SCS-microinjector to improve drug delivery (and standard of care) for treating wet AMD, diabetic macular edema (DME), and glaucoma. Based on his peer retinal specialists rapidly trying new and improved products, he anticipates broad use of Zuprata about 6-12 months after potential approval (if reliably reimbursed) and recommends that Clearside pursue a new CPT code for SCS delivery as the current CPT 67028 code for intravitreal injections (IVT) is the most used of all medical specialties and he anticipates reduced reimbursement for this code in the future."
No change to the price target of $28.
Shares of Clearside Biomedical closed at $7.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades Timken (TKR) to Hold
- BMO Capital Reiterates Outperform on Costco Wholesale (COST) Following 1Q Report
- Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesLiana Moussatos
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!